FSCN1 and neoplasm: Our results also showed that the treatment of METRO-TOPO (6-weeks EE) downregulates FSCN1 expression in subclonal populations in aggressive mCRPC/NEPC 3D tumor models, whereas CONV-TOPO resulted in increased expression (P < 0.05).